A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma (SUNRISE)

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2023
This article has no abstract
Epistemonikos ID: 2f3b1032f866026624d9a5e6ec34af5d60573999
First added on: Apr 11, 2025